F. Pareja

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

APOBEC3 mutagenesis drives therapy resistance in breast cancer

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

This paper develops a multimodal transformer model using H&E images and text reports to predict recurrence scores in hormone receptor-positive breast cancer, achieving high accuracy and generalizability.

Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

This study uses spatial molecular profiling to show that mixed invasive ductal-lobular breast cancers have distinct molecular subtypes, oncogenic signatures, and mutations in different tumor regions, leading to prognostic uncertainty and therapeutic challenges.

ERα-LBD, a novel isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance

The paper identifies ER-LBD, a novel estrogen receptor alpha isoform, which promotes breast cancer growth and resistance to endocrine therapy.

Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes

This study identifies distinct immune and malignant cell phenotypes in ovarian cancer linked to specific mutational processes and anatomic sites.